NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market on Friday that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase 90,000 additional shares of its stock at $10 per share.
As a result, the total gross proceeds from the offering are expected to be $6.9 million, Cancer Genetics said.
Aegis Capital was the sole book-running manager on the offering while Feltl and Co. acted as the co-manager.
The Rutherford, NJ-based cancer diagnostics firm went public last week, offering 600,000 shares of its stock at $10 per share. Cancer Genetics trades on the OTCQB Marketplace under ticker symbol "CGIX".